Alexandria S. Coles

Alexandria S. Coles

Auto-generated profile, based on publicly available information

Alexandria S. Coles

Centre for Complex Interventions, Centre for Addictions and Mental Health, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2018 in The American Journal on Addictions
Verified
Journal Article
Closed access
PDF file
ACAlexandria S. Coles
Alexandria S. Coles
KKKarolina Kozak
Karolina Kozak
TGTony P. George
Tony P. George

15 December 2021 in Frontiers in Psychiatry
Verified
Journal Article
Open access
ACAlexandria S. Coles
Alexandria S. Coles
DKDunja Knezevic
Dunja Knezevic
TGTony P. George
Tony P. George
CCChristoph U. Correll
Christoph U. Correll
JKJohn M. Kane
John M. Kane
DCDavid Castle
David Castle
Objectives: Co-occurring substance use disorders (SUDs) among individuals with schizophrenia are a prevalent and complex psychiatric comorbidity, which is associated with increased symptom severity, worsened illness trajectory and high rates of treatment non-adherence. Recent evidence suggests that the use of long-acting injectable (LAI) antipsychotics may provide an effective treatment option for individuals with this dual-diagnosis.Methods: A systematic review of the literature was conducted using the databases PubMed, PsychInfo and Google Scholar for English-language studies, investigating the use of LAIs in co-occurring schizophrenia and substance use disorders (SCZ-SUDs).Results: Eight reports [one case study (n = 1), one case series (n = 8), three open-label retrospective studies (n = 75), and three randomized controlled trials (n = 273)] investigated the use of LAI antipsychotics in 357 participants with SCZ-SUDs [alcohol use disorder: 5 studies, n = 282; cocaine use disorder: 5 studies, n = 85; amphetamine use disorder: 1 study, n = 1; cannabis use disorder: 3 studies, n = 160; opioid use disorder: 3 studies, n = 19; methylenedioxymethamphetamine (MDMA) use disorder: 2 studies, n = 9; ketamine use disorder: 1 study, n = 4] and were included in this systematic review. Findings indicate significant improvements in substance use related outcomes across 7 of 8 studies, while in 6 of 8 studies, significant improvements in psychopathology-related outcomes were reported.Conclusions: LAI antipsychotics may be an efficacious intervention option for the treatment of SCZ-SUDs. However, varying methodological rigor, generally small sample sizes and heterogeneity of samples, settings, substances of abuse, tested LAIs and comparators, as well as psychosocial cotreatments and level of reported detail across studies requires that these findings be considered preliminary and interpreted with caution. Further research is required to better understand the effects of LAIs among individuals with SCZ-SUDs.

11 May 2019 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
ACAlexandria S. Coles
Alexandria S. Coles
JSJulia Sasiadek
Julia Sasiadek
TGTony P. George
Tony P. George

22 November 2019
Verified
Book Chapter
Closed access
PDF file
FAFariya Ali
Fariya Ali
ABAli Bani-Fatemi
Ali Bani-Fatemi
IBIsabelle E. Bauer
Isabelle E. Bauer
BBBernhard T. Baune
Bernhard T. Baune
VBVenkat Bhat
Venkat Bhat
Xiangyang ZhangXiangyang Zhang
Xiangyang Zhang